The ITA, on behalf of IRONMAN, hereby reports that U.S. athlete Collin Chartier has committed an anti-doping rule violation (ADRV) under article 2.1 of the IRONMAN Anti-Doping Rules (IRONMAN ADR) for the presence of erythropoietin (EPO) in a sample collected out-of-competition by IRONMAN on 10 February 2023.
The sample collected from Collin Chartier returned an adverse analytical finding for the non-specified prohibited substance EPO. EPO is prohibited under the 2023 World Anti-Doping Agency’s Prohibited List as peptide hormone (S2). EPO stimulates erythropoiesis (red blood cell production) and can modify the body’s capacity to transport oxygen and, therefore, increase stamina and performance.
Collin Chartier did not challenge the ADRV and agreed with the consequences proposed by the ITA. Due to his early admission, the athlete is entitled to a one-year reduction in the otherwise four-year period of ineligibility usually imposed for an ADRV for the presence of EPO as set forth in article 10.8.1 of the IRONMAN ADR*. Accordingly, this case was resolved via an acceptance of consequences pursuant to article 8.3.1 of the IRONMAN ADR. The athlete’s period of ineligibility across all sports runs until 26 March 2026 and any competition results obtained by Mr. Chartier after the positive test of 10 February 2023 are disqualified.
The prosecution of the matter was handled independently by the ITA on behalf of IRONMAN. As a private corporation conducting triathlon events, IRONMAN is the first private, non federation sports company to formally adhere to the World Anti-Doping Code.